Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

Obsessive-Compulsive Disorder Clinical Trial

Official title: Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

Status Recruiting

Clinical Trial Summary

The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compulsive disorder.

Clinical Trial Description

The proposed study intends to recruit 2 groups:

1. Matched healthy control participants will be imaged with one fMRI at baseline as a no-treatment comparison group; and

2. a randomized, double-blind group of unmedicated OCD participants who will be assigned to begin either immediate or placebo-delayed treatment, and who will be imaged with fMRIs at baseline and over the course of treatment with a selective serotonin reuptake inhibitor (SSRI), fluoxetine.

Hypothesis-driven analyses and exploratory analyses will be performed in parallel.

This study will address the following Specific Aims:

1. Identification of neural dysconnectivity associated with OCD symptomatology.

2. Characterizing neural markers of clinical response to SSRI pharmacotherapy.

3. Mapping neural predictors of clinical response to pharmacotherapy. ;

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder

• NCT number: NCT04131829
• Study type: Interventional
• Source: Yale University
• Contact: Yale OCD Research Clinic
• Phone: 1-855-623-9253
• Email: ocd.research@yale.edu
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 14, 2019
• Completion date: July 31, 2024